Table 1.

Recommendations for government policies on automated BP measuring devices (BPMDs)^a.

Build strong regulatory capacity to ensure a smooth and rapid transition to the sole use of validated automated BPMDs for routine clinical use within a strategic approach to hypertension/cardiovascular disease/non-communicable disease prevention and control, emphasizing primary healthcare facilities.

Develop national capacity for independent validation testing of all automated BPMDs, preventing conflicts of interest.

Enable universal access to validation testing protocols and develop checklist/s to provide evidence that validation testing protocols have been followed. This should include a process of regular review and updating.

Regulate the sales (including those online) of automated BPMDs to prohibit the marketing of clinical devices that have either failed validation testing or have not undergone validation testing or where “equivalence” to a validated BPMD is not clearly proven.

Regulate the sale and marketing of automated BPMDs to require packaging that clearly and prominently indicates whether the device has passed validation testing, and for which population (e.g., general population, pregnancy, large arm circumference, atrial fibrillation, children).

Develop an easy-to-access list of validated (including equivalent) automated BPMDs that are readily available in each region. Ensure that this list is regularly reviewed.

Develop policies to ensure equitable and affordable access to validated automated BPMDs including locations where electricity is unreliable.

Develop a procurement policy that includes only validated automated BPMDs for routine clinical use.

Develop technical capacity (e.g., clinical engineers) to appropriately select, maintain and support the use of validated automated BPMDs.

^aAdapted from ref. [1].